Dr Karine ROGET is the Chief Scientific Officer at Nexbiome. Prior to this position, she has worked in the R&D department of several start-up companies focusing on drug and biomarker development.
Karine holds a PhD in immunology from Université Pierre et Marie Curie and Institut Pasteur (Paris, France) and has completed post-doctoral training in cell signaling and immunology at the National Institute for Medical Research (London, United Kingdom).
C. Petit, I. Dubus, C. Heuclin, K. Roget and JP. Vannier (2016). Hypoxia promotes chemoresistance in Acute Lymphoblastic Leukemia cell lines by modulating death signaling pathways. BMC Cancer, 16(1):746.
AN. Burska, K. Roget, M. Blits, L. Soto Gomez, F. van de Loo, LD. Hazelwood, CL. Verweij, A. Rowe, GN. Goulielmos, LG. van Baarsen and F. Ponchel (2014). Gene expression analysis in RA: towards personalized medicine. Pharmacogenomics Journal, 14(2):93-106.
K. Roget, A. Ben-Addi, A. Mambole-Dema, T. Gantke, HT. Yang, J. Janzen, N. Morrice, D. Abbott and SC. Ley (2012). IKK2 regulates TPL-2 activation of ERK1-2 MAP kinases by direct phosphorylation of TPL-2 serine 400. Molecular and Cellular Biology, 32(22):4684-90.
K. Roget, M. Malissen, O. Malbec, B. Malissen and M. Daëron (2008). Non-T Cell Activation Linker promotes mast cell survival by dampening the recruitment of SHIP1 by Linker for Activation of T cells. The Journal of Immunology, 180(6):3689-98.
O. Malbec, K. Roget, C. Schiffer, B. Iannascoli, A. R. Dumas, M. Arock, and M. Daëron (2007). Peritoneal Cell-derived Mast Cells: an in vitro model of mature serosal-type mouse mast cells. The Journal of Immunology, 178(10):6465-75.